Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 3, 2016, details the completion of Evolent Health, Inc.'s acquisition of Valence Health, Inc. The transaction involved an amendment to the original Merger Agreement dated July 12, 2016, and the subsequent closing of the merger on October 3, 2016. Upon closing, Valence Health, Inc. merged into Electra Merger Sub, LLC, a wholly-owned subsidiary of Evolent, which was renamed Valence Health, LLC.
Key Financial Metrics and Transaction Details
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, or margins for the reporting period. The primary financial data relates to the acquisition consideration:
- Total Closing Merger Consideration: $219.4 million (based on Evolent's stock price on October 3, 2016).
- Cash Consideration: $50.3 million paid from cash on hand.
- Share Consideration: Approximately 7.05 million shares of Evolent Class A common stock issued.
- Dilution Impact: Shares issued represent approximately 10.5% of Evolent's total issued and outstanding common stock post-merger.
- Contingent Consideration: Reduced to $12.38 million (payable in up to 951,576 shares) based on 2016 business activity.
Material Changes Versus Prior Agreement
The October 3, 2016 Amendment modified the original July 2016 Merger Agreement in the following ways:
- Increased Consideration: The total consideration increased by $41.1 million compared to the original agreement. This included a $15.3 million increase in cash and an additional 1.58 million shares of stock.
- Earn-out Adjustment: The increase reflects the achievement of a portion of the previously agreed earn-out prior to closing, alongside an adjustment to the earn-out threshold.
- Asset Exclusion: Contracts serving state insurance cooperatives that announced shutdowns will not be transferred to a separate entity owned by former Valence stockholders. Instead, the Surviving Entity will retain these contracts solely for run-out services, with Evolent entitled to indemnification for related losses.
- Equity Treatment: All outstanding Valence options and warrants were accelerated to full vesting and subsequently canceled for no consideration at the effective time of the merger.
Guidance, Outlook, Risks, and Corporate Governance
Corporate Governance Change: Following the merger, UPMC, TPG Global affiliates, and The Advisory Board Company no longer control a majority of voting power. Evolent is no longer classified as a "controlled company" under NYSE rules.
Risks and Contingencies: The filing outlines significant risks associated with the acquisition, including:
- Integration challenges, delays, and unanticipated costs.
- Loss of key employees and disruption to ongoing business operations.
- Potential liabilities from Valence regarding intellectual property infringement or data privacy violations.
- Uncertainty regarding the realization of anticipated synergies and cost savings.
- General market risks including regulatory changes in healthcare and competition.
Financial Reporting: Pro forma financial information and financial statements of the acquired business are not included in this filing but will be submitted within 71 calendar days.
Investor Verification Checklist
- Verify the final closing price of Evolent stock on October 3, 2016, to confirm the $219.4 million total valuation of the deal.
- Review the upcoming pro forma financial statements (due within 71 days) to assess the impact of the acquisition on Evolent's balance sheet and earnings.
- Monitor the integration progress of Valence Health, LLC, specifically regarding the retention of key personnel and the management of run-out services for state insurance cooperatives.
- Track the vesting and potential issuance of the remaining contingent share consideration ($12.38 million) based on 2016 performance metrics.
- Assess the implications of Evolent losing its "controlled company" status on future corporate governance requirements.